The Latest Advancements in Cutaneous Melanoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 April 2026 | Viewed by 21
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cutaneous melanoma (CM) is one of the most aggressive forms of skin cancer, with a rising incidence worldwide. Early-stage CM can often be cured with surgical excision, while sentinel lymph node biopsy and complete lymph node dissection are considered in selected patients. For patients with locally advanced or metastatic disease, treatment options have evolved dramatically over the past decade. Immune checkpoint inhibitors, such as anti-PD-1 antibodies (nivolumab and pembrolizumab) and combination therapy with anti-CTLA-4 antibodies (ipilimumab), have significantly improved survival. Targeted therapies, such as BRAF and MEK inhibitors for patients harboring BRAF V600 mutations, have also become important first-line options. For patients who progress after initial therapies, ongoing clinical trials continue to explore novel immunotherapies, targeted agents, and combination strategies. Despite recent progress, challenges remain in early detection, resistance, and long-term outcomes.
We invite you to contribute original research or reviews to our Special Issue on "Cutaneous Melanoma" in Cancers. Topics of interest include, but are not limited to, the following:
- Diagnosis: Biomarkers, dermoscopy, and advanced imaging techniques.
- Treatment: Including surgery, adjuvant and neoadjuvant therapies, radiotherapy, and systemic treatments.
- Emerging Strategies: Novel immunotherapies, targeted agents, and resistance mechanisms.
I look forward to receiving your contributions.
Dr. Zhenyu Ji
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cutaneous melanoma
- skin cancer
- immunotherapy
- targeted therapy
- melanoma biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
